Thrombocytopenia with and without thrombosis following COVID-19 vaccination: long-term management

CONCLUSION: Two of 4 patients with VITT developed refractory thrombocytopenia successfully treated with intravenous immunoglobulin, corticosteroids, and plasma exchange therapy. Patients with VITT remained on anticoagulation for at least 9 months due to persistently positive diagnostic tests. Four of 5 patients with immune thrombocytopenia received intravenous immunoglobulin and corticosteroids with good recovery. Patients who received a subsequent COVID-19 mRNA vaccine had no adverse hematologic effects.PMID:38550529 | PMC:PMC10973182 | DOI:10.1016/j.rpth.2024.102357

Source: Thrombosis and Haemostasis - March 29, 2024 Category: Hematology Authors: M Ge D Ladha J Lymer S Pancic M Carrier G Le Gal L A Castellucci Source Type: research